Scale -


  • PAT is 327 Rs Cr; Annual Decline is -21 %; Continuous Decline over 3 years; in Bottom Quartile; 5 Year CAGR is -23 %
  • Revenue is 1837 Rs Cr; Continuous Decline over 3 years; in Bottom Quartile; 5 Year CAGR is -11 %
  • Ebitda is 511 Rs Cr; in Bottom Quartile; 5 Year CAGR is -12 %
  • PBT is 112 Rs Cr; in Bottom Quartile; 5 Year CAGR is -23 %
  • Quarterly Revenue is 438 Rs Cr; in Bottom Quartile

Profitability -


  • Quarterly Profit margin is 19 %; in Top Quartile
  • PAT Margin is 17.78 %; Annual Decline is -13 %; Continuous Decline over 3 years; 5 Year CAGR is -14 %

Return -


  • ROCE is 62.05 %; in Top Quartile; 5 Year CAGR is 17 %
  • ROA is 26.03 %; in Top Quartile
  • ROE is 43.6 %; in Top Quartile; Continuous Decline over 3 years
  • Asset Turnover is 128 %; in Top Quartile

Efficiency -


  • Inventory Turnover Ratio is 4.53; Annual Growth is 31 %; Continuous Growth over 3 years; 5 Year CAGR is 33 %
  • Operating cash flow is 438 Rs Cr; in Bottom Quartile

Solvancy -


  • Debt/Equity is 0; in Bottom Quartile
  • Total Debt is 0 Rs Cr; in Bottom Quartile

Quality -


  • Operating cashflow/PAT is 134 %; Annual Growth is 20 %; Continuous Growth over 3 years; 5 Year CAGR is 23 %
  • Other Expenses/Total Expenses is 19 %; Continuous Decline over 3 years; in Bottom Quartile
  • Operating cashflow/ebitda is 86 %; in Top Quartile
  • Exceptional Items/PBT is -6 %; in Bottom Quartile
  • Current Tax/PAT is 38 %; Annual Growth is 24 %; in Top Quartile
  • Change in Inventories/Total Expenses is 10 %; Annual Growth is 156 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 51 %

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
750% Dividend: Pharma Stock Jumps 7% After Announcing Strong Results and Dividend
Sanofi India (NSE:SANOFI): Why Are Nine-Month Results and an Interim Dividend Reported Together?
Sanofi India Q3 Profit Jumps 54% to ?117 Crore as Insulin Grows 9% and Public Sector Sales Surge 85%; ?75 Interim Dividend
Sanofi India declares Rs. 75 interim dividend per share for financial year 2026
Sanofi India Dividend 2026: Rs 75 per share payout in Q3, check record date
Sanofi India Q3 Results: Declares 750% dividend; profit jumps 54% to Rs 1,167 crore, revenue rises 3.4% to Rs 4,917 crore
Sanofi India Q3 results: Profit rises 53.6% YoY to Rs 117 crore, EBITDA margin expands
Sanofi Consumer Healthcare India Limited reports Q3’26 Revenue at ?2,631 MN, Net Profit at ?1,027 MN
Sanofi’s Qfitlia Receives Marketing Approval in India
Sanofi India (NSEI:SANOFI) Stock Forecast & Analyst Predictions